Silence Therapeutics PLC Director/PDMR Shareholding (4346H)
December 03 2020 - 03:45AM
UK Regulatory
TIDMSLN
RNS Number : 4346H
Silence Therapeutics PLC
03 December 2020
Director Dealing
3(rd) December 2020
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN
("Silence" or "the Company"), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today announces that, on the 30th
November 2020, 4,500 Shares were purchased by Dr. Steven Romano,
Non-Executive Director of the Company, at $5.58 per share.
Following this purchase, Dr. Steven Romano is interested in
14,500 ordinary shares (0.02%) of the issued share capital of the
Company.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Dr. Steven Romano
--------------------------- ----------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------------
a) Position / status Non-Executive Director
--------------------------- ----------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- ----------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- ----------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- ----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of Ordinary Shares of 5 pence each in Silence
the financial instrument, Therapeutics plc
type of instrument
Identification
code ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- ----------------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares in Silence
Therapeutics plc
--------------------------- ----------------------------------------------
c) Prices(a) and volume(s) Price(s) Volume(s)
$5.550 1,000 shares
-------------
$5.575 1,000 shares
-------------
$5.595 500 shares
-------------
$5.595 1,000 shares
-------------
$5.595 1,000 shares
-------------
--------------------------- ----------------------------------------------
d) Aggregated information Aggregate Volume: 4,500 shares
- Aggregated volume Metric for Quantity: Shares
- Price Aggregated Volume Price per share: $5.5806
--------------------------- ----------------------------------------------
e) Date of the transaction 30 November 2020 (Time zone: Eastern Standard
Time)
--------------------------- ----------------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- ----------------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR & Corporate Communications
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
US IR Tel: +1 (443) 213-0505
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
medical need. Silence's proprietary technology can be used to
engineer short interfering ribonucleic acids (siRNAs) that bind
specifically to and silence, through the RNAi pathway, almost any
gene in the human genome to which siRNA can be delivered. Silence's
wholly owned product candidates include SLN360 designed to address
the high and prevalent unmet medical need in reducing
cardiovascular risk in people born with high levels of
Lipoprotein(a) and SLN124 to address beta-thalassemia and
myelodysplastic syndrome. Silence is also developing a C3 targeting
programme, SLN500, in partnership with Mallinckrodt Pharmaceuticals
to reduce the expression of the C3 protein for the treatment of
complement pathway-mediated diseases. Silence maintains ongoing
research and collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals and Takeda. For more information, please visit:
https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGCBDDDSGDGGX
(END) Dow Jones Newswires
December 03, 2020 04:45 ET (09:45 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2023 to Mar 2024